MRD Leukemia Panel - (B-ALL) by Flow Cytometry, EDTA Bone Marrow**

Flow for B-ALL MRD (Minimal Residual Disease) is a diagnostic test with clinical utility in the assessment of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL) patients. Minimal residual disease refers to the small number of leukemic or cancer cells that remain in the body after treatment. Flow cytometry, a technique that utilizes fluorescently labeled antibodies, is used to analyze and quantify these residual leukemic cells in the bone marrow or peripheral blood. The detection and monitoring of MRD are crucial in assessing treatment response, predicting relapse, and guiding further therapeutic interventions. By evaluating the level of MRD using flow cytometry, healthcare professionals can determine the effectiveness of treatment and adjust therapy accordingly, aiming to achieve and maintain minimal levels of residual disease. The Flow for B ALL MRD test plays a vital role in the management of B ALL patients, aiding in treatment decisions and optimizing long-term outcomes.